Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.57 HKD | -0.45% | +9.50% | -9.50% |
26/04 | CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S | CI |
24/04 | CSPC Pharmaceutical's EBT Buys 8.5 Million Shares | MT |
Evolution of the average Target Price on CSPC Pharmaceutical Group Ltd.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering CSPC Pharmaceutical Group Ltd.
Nomura | |
UBS |
EPS Revisions
- Stock Market
- Equities
- 1093 Stock
- Consensus CSPC Pharmaceutical Group Ltd.